Drug and alcohol dependence · 2025
Outpatient initiation of direct-to-inject buprenorphine.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rosenwohl-Mack Sarah, Heeney Megan, Samuel Lysa, Anderson Erik, Herring Andrew A, Sirey Lauren Roller, Peterson Damian, Bazazi Alexander R, Snyder Hannah, Suen Leslie W
Аннотация
BACKGROUND: Fentanyl-involved overdose deaths have surged, yet buprenorphine remains underutilized for opioid use disorder (OUD) treatment, partly due to the risk of precipitated withdrawal during buprenorphine initiation. Direct-to-inject (DTI) buprenorphine using weekly long-acting injectable formulations may reduce this risk with a gradual and sustained rise in serum buprenorphine levels.
OBJECTIVE: To evaluate 90-day treatment retention, withdrawal tolerability, and associated factors following DTI buprenorphine initiation across multiple outpatient safety-net settings.
METHODS: We conducted a retrospective cohort study of 131 DTI initiations among 114 patients with OUD across San Francisco and Oakland safety-net clinics from March 2024 to May 2025. Patients were initiated on weekly long-acting buprenorphine. We assessed withdrawal severity in the first 24h and calculated continuous treatment retention at 7, 30, and 90 days using pharmacy and chart data.
RESULTS: Mean age was 42 years; 79 % reported fentanyl use, and 67 % were unstably housed or unhoused. In the 24h after injection, 37 % experienced no withdrawal, 31 % experienced mild-moderate withdrawal, and 11 % experienced severe withdrawal, with 21 % missing data. Overall, 72 % continued buprenorphine beyond initial injection, with most transitioning to monthly formulations. Retention rates were 69 % at 7 days, 68 % at 30 days, and 43 % at 90 days. No demographic or clinical factors predicted 90-day retention.
CONCLUSIONS: In this retrospective study, DTI buprenorphine initiation demonstrated favorable tolerability and retention in a high-risk population across diverse outpatient settings. This approach may offer a viable pathway to long-acting buprenorphine treatment for individuals using fentanyl who may not tolerate traditional initiation methods.
OBJECTIVE: To evaluate 90-day treatment retention, withdrawal tolerability, and associated factors following DTI buprenorphine initiation across multiple outpatient safety-net settings.
METHODS: We conducted a retrospective cohort study of 131 DTI initiations among 114 patients with OUD across San Francisco and Oakland safety-net clinics from March 2024 to May 2025. Patients were initiated on weekly long-acting buprenorphine. We assessed withdrawal severity in the first 24h and calculated continuous treatment retention at 7, 30, and 90 days using pharmacy and chart data.
RESULTS: Mean age was 42 years; 79 % reported fentanyl use, and 67 % were unstably housed or unhoused. In the 24h after injection, 37 % experienced no withdrawal, 31 % experienced mild-moderate withdrawal, and 11 % experienced severe withdrawal, with 21 % missing data. Overall, 72 % continued buprenorphine beyond initial injection, with most transitioning to monthly formulations. Retention rates were 69 % at 7 days, 68 % at 30 days, and 43 % at 90 days. No demographic or clinical factors predicted 90-day retention.
CONCLUSIONS: In this retrospective study, DTI buprenorphine initiation demonstrated favorable tolerability and retention in a high-risk population across diverse outpatient settings. This approach may offer a viable pathway to long-acting buprenorphine treatment for individuals using fentanyl who may not tolerate traditional initiation methods.